Use of known agonists of the central cannabinoid receptor CB1

US6525087B2 · kind B2 · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Joachim Mittendorf · Wuppertal, DE
• Jurgen Dressel · Radevormwald, DE
• Michael Matzke · Wuppertal, DE
• Jürgen Franz · Haan, DE
• Peter Spreyer · Düsseldorf, DE
• Verena Vöhringer · Wuppertal, DE
• Joachim Schumacher · Wuppertal, DE
• Arno Friedl · Bensberg, DE
• Ervin Horvath · Leverkusen, DE
• Frank Mauler · Overath, DE
• Jean De Vry · Stolberg, DE
• Reinhard Jork · Haan, DE

Key dates

• Filing date: May 29, 2001
• Grant date: Feb 25, 2003
• Expiry date: Jul 26, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.